• Hikma recently narrowed its expected 2026 Group operating-profit range to $740 million-$760 million. Branded has been outperforming, Hikma Rx profitability has been improving and Injectables has been stabilising, while management continues to invest in launches and R&D.
• Vohra will also join Hikma's Audit Committee and its Nomination and Governance Committee on appointment.
Investors should watch consumables demand, device placement, regional sales, product development and cash generation after the tender.
Investors should watch study initiation, regulatory submissions, clinical data,Partnershipterms and cash commitments across the development portfolio.
Cash and equivalents increased to £2.9 million, helped by £3.2 million ofEquityraised during the year. The company said it expects continued revenue growth and an improved EBITDA position in the 2027 financial year, but noted that short-term delays affected the first quarter of the …
The Rule 2.9 announcement, published at 1:42 p.m. on 4 November, stated that the company had 221,042,797 ordinary shares of 5p each in issue and admitted to trading on AIM, with none held in treasury, so all carry voting rights. The summary of the …
For the first half of 2026, underlying revenue, which excludes Arizona Medicaid, rose 18.8% to $31.9 million. Reported revenue increased 10.8% to $35.3 million. EBITDA grew 16.6% to $3.6 million, andOperating Cash Flowwas positive at $0.9 million, a marked improvement on the outflow of …
Founded in 2008, Aptamer develops Optimer binders, synthetic alternatives to antibodies for life sciences, diagnostic and therapeutic uses. It earns fee-for-service research revenue and builds proprietaryAssetsthat it can license for royalties and supply.
According to a summary of the interim results,Revenuewas £0.2m against £1.0m a year earlier,Research and Developmentcosts rose to £1.9m from £1.3m, and the loss after tax widened to £3.0m from £2.0m. Cash was £3.2m, up from £1.9m. The figures come from an AI-generated summary …
• Sector conditions can amplify moves in smaller UK-listed shares.